September 22, 2023 Release Highlights Copied

09/22/20232023 VBCRelease note

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

National Comprehensive Cancer Network (NCCN) Distress Thermometer Dashboard

The new NCCN Distress Thermometer dashboard is a tracking mechanism that empowers your practice with invaluable insights. This dashboard is integrated with iKnowMed Generation 2, offering a comprehensive overview of patients’ distress levels and ensuring every documented distress level is captured and visualized on a weekly basis.

Use the NCCN Distress Thermometer Dashboard to meet the requirements of MIPS Measure #487: Screening for Social Drivers of Health (planned for release in early 2024), which will assess the total number of patients who have completed a screening for health-related social needs.

NCCN Distress Thermometer Dashboard Features

To use the NCCN Distress Thermometer dashboard:

  1. Make one or more selections (callouts 1-6) to filter the dashboard by:
    • Practice
    • Division
    • Location
    • Provider
    • Visit Date
    • VBC Program
  2. The dashboard includes a dynamic Patient Count (callout 7) that adjusts based on your filters.
    • A patient is only counted once per location within the dashboard with their most recent screening displayed. This means if a patient is treated at multiple locations in the same week, they will be displayed for each location.

  3. To export the report, click the Export Dropdown Functionality button and select the Crosstab option (callout 8).
  4. From the Download Crosstab window, select Patient Details (callout 9), choose your preferred document format (callout 10), and click the Download button (callout 11) to complete the data export.

    NOTE: Choose the CSV format for the most optimal experience. Once downloaded, you can save the file in Excel format.

MIPS Quality Measures Dashboard

The dashboard has also been updated to reflect the below refinement(s) for:

Measure Description
MIPS #453: Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (Inverse Measure)
  • 2023 Measure Specification update to better capture active oral chemotherapy treatment. Patients will be “numerator met” when receiving oral chemotherapy within the last 14 days if an oral cancer directed therapy is refilled or newly prescribed during the last 14 days of life. Active medications prescribed prior to the last 14 days of life are considered “numerator not met”.
  • Technical Refinement to attribute Numerator credit to the “Prescribing Clinician”.
 Practice-level results will be minor; performance rates for individual clinicians will be more significant due to the attribution update to associate numerator criteria with a single prescribing clinician.

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

Measure Description

MIPS Quality Measures Dashboard
#047 Advance Care Plan
#104 Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130 Current Medications Documentation
#134 Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143 Pain Intensity Quantified
#144 Pain Care Plan
#226 Tobacco Screening and Cessation
#236 Controlling High Blood Pressure
#374 Closing the Referral Loop
#451 RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452 Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#453 Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 147 Days of Life (Inverse Measure)
#457 Patients Admitted to Hospice for < 3 Days
PIMSH#1 Advance Care Planning in Stage 4 Disease
PIMSH#2 Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4 Patient-Reported Pain Improvement
PIMSH#8 Mutation Testing for Lung Cancer
PIMSH#9 Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10 Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15 Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16 Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center